Product Reports Resources Pricing Login Book a demo
COMPANY PROFILE

Apollo Endosurgery

Explore full profile

Less invasive therapies for the treatment of obesity

Austin, United StatesFounded 2006Biotech & Life Sciences
Valuation $580M Market cap · 2023
Revenue $75M Latest reported FY

About Apollo Endosurgery

Apollo Endosurgery, Inc. is a medical technology company focused on revolutionizing patient care through the development of innovative endoscopic surgical products. The company specializes in minimally invasive procedures, particularly in the field of bariatrics, which deals with weight loss surgeries, and other gastrointestinal interventions. Apollo Endosurgery serves a diverse range of clients, including hospitals, clinics, and specialized medical practitioners across more than 80 countries.

Operating in the global healthcare market, Apollo Endosurgery targets the growing demand for less invasive surgical options. Their product portfolio includes devices like the Orbera Intragastric Balloon, which helps patients lose weight without the need for traditional surgery, and the OverStitch Endoscopic Suturing System, which allows for complex suturing procedures to be performed endoscopically (using a flexible tube inserted into the body).

The company's business model revolves around the development, manufacturing, and distribution of these medical devices. Revenue is generated primarily through the sale of these products to healthcare providers and medical institutions. Additionally, Apollo Endosurgery offers training and support services to ensure that medical professionals can effectively use their products, further enhancing their revenue streams.

Apollo Endosurgery is listed on the NASDAQ under the ticker symbol APEN, indicating its status as a publicly traded company. This listing provides the company with access to capital markets, enabling it to fund research and development, expand its product offerings, and enter new markets.

In summary, Apollo Endosurgery is a key player in the medical technology sector, focusing on innovative, minimally invasive surgical solutions that improve patient outcomes and reduce recovery times.

Source: Dealroom company data

At a glance

Status
Listed
Founded
2006
Headquarters
Austin, United States
Listing
IPO 2005
Employees
148
Open positions
None listed
Dealroom signal
63.2/100
Industry
Health
Sub-industry
BioTechnology, Medical Devices
Sector
Biotech & Life Sciences, Biotechnology, Weight Management, Biomedical, Patient Care, Nutrition, Non-Invasive medical devices and treatments, Spinout, Metabolism, Biotech and Pharma
Business model
Manufacturing
Client focus
b2c
Investment activity
1 company, latest Sep 2016
Capital deployed
—
Preferred round
ACQUISITION

Funding history

10 recorded events

Company financing events and reported valuations.

Deal typeDateAmountValuationInvestorsSource
ACQUISITIONOther financing Nov 2022 $615M $615M Boston Scientific ↗
POST IPO DEBTDebt Dec 2021 $35M — Innovatus Capital Partners —
Showing the latest 2 of 10 recorded eventsBook a demo for the full funding history →

Financials

Revenue over time

Revenue, earnings and other financial measures where available. Years marked “E” are estimates.

YearRevenueGrowth
2026 $75M 0%
2025 $75M 0%
2024 $75M 0%
2023 $75M 0%
2022 $75M +24.3%
2021 $60M +34.4%
2020 $45M —
Company filings, research estimates and Dealroom dataBook a demo for the full financial model →

Growth signals

Apollo Endosurgery website traffic

Latest recorded traffic for Apollo Endosurgery is 410 monthly website visits, down 70.7% over the last three months. Apollo Endosurgery's team declined 44.8% over the past year.

Latest monthly visits410 3-month web change-70.7% 1-year team growth-44.8%
Summary metrics are public; monthly history is available with a demoCompare with peers →

Similar companies

Closest operating peers by Dealroom taxonomy

Company identity and context are open; selected comparison metrics preview what is available on the platform.

Showing 8 of the closest matchesCompare every metric →

Investments and acquisitions

Capital deployed

Recent portfolio relationships for companies that also act as investors or acquirers.

Investors

13 investors on the cap table

From Dealroom's funding and investor records, grouped by the round each investor first entered.

Series A5 investors entered at this stage

  • PTV Healthcare Capital
  • HIG Capital
  • Remeditex Ventures
  • Novo Holdings
  • CPMG

Series B and later5 investors entered at this stage

  • Midcap Financial
  • Oxford Finance
  • UT Horizon Fund
  • Craig-Hallum Capital Group
  • Innovatus Capital Partners

Other known investors3 additional known investors

  • Boston Scientific
  • Johns Hopkins University
  • University of Texas Medical Branch
Team profiled 19 named & role-tagged
Founders Hidden — book a demo/100 quality score
Key operators 5 quality Hidden — book a demo/100
Potential founders Hidden — book a demo likely future founders
Startup mafia Hidden — book a demo alumni-founded startups
Talent movements Hidden — book a demo in · Hidden — book a demo out past 12 months

Source: Dealroom Talent Intelligence.

Global footprint

Workforce and web traffic by country
Workforce by country
8 countries with
team presence
🇺🇸 United States64.4%
🇨🇷 Costa Rica20.3%
🇧🇷 Brazil5.1%
🇦🇺 Australia1.7%
🇮🇹 Italy1.7%
Top 5 of 8 shown

Market sentiment

Posts on X, past 7 days

An AI-synthesised read of the highest-engagement posts about Apollo Endosurgery on X, ranked by likes and reposts, corporate channels excluded.

Reading the room on X — pulling top posts and synthesizing themes…

Source: X recent search ranked by engagement (likes + retweets) · Synthesis by Claude · Cached for 1 hour

See Apollo Endosurgery’s full profile on Dealroom

Request a free trial to see the complete deal history, financials, people graph and growth signals.

Takes under a minute. Already use Dealroom? Log in.